PharmaGEO vs generic GEO tools.

A wave of generative engine optimization platforms has emerged since 2024. Profound raised at a $700M valuation, Evertune is backed by WPP, Semrush and Ahrefs added Brand Radar and AI Overview tracking. They all do roughly the same thing well: they show how a consumer brand appears in ChatGPT, Perplexity, Gemini, Copilot, AI Overviews, and AI Mode, and they recommend content moves to improve that visibility.

Pharma is not a consumer brand category. The audience is regulated. The content is regulated. The risks of bad answers are not commercial, they are clinical. The LLMs that matter are not always the ones the marketing tools track. This article explains, in concrete terms, the gap between generic GEO tools and what a pharma launch team actually needs, and how PharmaGEO is built around that gap.

Why pharma GEO is a different problem

Five things make pharmaceutical GEO structurally different from B2C, SaaS, retail, or hospitality GEO. None of them is solved by adding "healthcare" to a prompt list.

1. The unit of analysis is the indication, not the brand. A consumer brand answers one question: how do I appear when somebody types my name. A pharma brand has to answer many: how do I appear for the molecule, for each indication, for each line of therapy, for each comparator class, in each country, in each language. Generic tools track brand prompts. Pharma needs prompts that look like clinical decision pathways.

2. The audience is not the buyer. Healthcare professionals are now the dominant search audience for pharma queries. According to Varn Health, 2026, more than 60% of European HCPs use generative AI weekly to look up clinical information. They do not type the way patients do. They use ICD codes, generic names, regimen language. Tools that mine consumer prompt streams miss the conversation entirely.

3. There is a clinical LLM layer that consumer tools do not see. A growing share of HCP queries never touches ChatGPT or Gemini. They go through purpose-built clinical engines: OpenEvidence (used daily by 40% of US physicians), Medwise, Tonic App (CE Class IIa medical device), Pulse Life, MedGPT, and others. These engines retrieve from peer-reviewed literature, guidelines, and regulatory documents, not from consumer crawls. If your brand is not visible there, it is invisible to your most influential audience, and no generic GEO tool will tell you.

4. The wrong answer is a pharmacovigilance signal. When ChatGPT recommends the wrong dosing, mentions an off-label use as if it were on-label, or cites a withdrawn study, the answer is not just bad marketing. It is a potential safety event. Pharma GEO has to flag those instances, log them, and route them through pharmacovigilance and medical affairs, the same way a misleading visual aid would be. Generic tools are not built to detect or escalate these.

5. Recommendations have to be MLR-ready. "Publish a long-form guide on retinal vein occlusion to capture more share of voice" is fine for a SaaS brand. For a pharma brand, every public claim has to clear medical, legal, and regulatory review. Recommendations that ignore promotional rules, fair-balance, off-label restrictions, EFPIA Code, IFPMA, FDA OPDP, ABPI, ANSM, Codeem, AIFA, etc., are unactionable. They cost time, they get rejected, they break the trust between brand and medical.

How the platforms compare

The matrix below compares PharmaGEO with the six most-cited GEO tools on capabilities that matter to a pharma launch or in-market team. Marks reflect public documentation as of May 2026 and our own evaluation of public demo material. We will refresh this table quarterly.

The five things only PharmaGEO does

What this means for a launch team

If your brand is consumer (an OTC analgesic, a cosmetic dermatology line, a wellness product), a generic GEO tool may be enough. Profound, Evertune, Otterly, and Peec.ai are excellent at what they do for those categories.

If your brand is prescription, regulated, or sold through HCPs, a generic GEO tool will give you a partial picture. You will track ChatGPT and Gemini, but miss OpenEvidence, where 40% of US physicians live. You will get content recommendations that fail MLR. You will not see pharmacovigilance drift before it becomes a complaint. You will benchmark against domains, not molecules.

PharmaGEO exists because none of the tools above were built for that reality, and bolting "healthcare" onto a consumer GEO tool will not bridge the gap. The methodology is published, the audit takes 7 working days, and the recommendations are written by analysts who have done MLR before.

Want to see the gap on your own brand? Request a sample report or get the full PharmaGEO Playbook.